Skip to main content
Signal8

Benitec Biopharma Inc. (BNTC)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Benitec Biopharma Inc. logo

Benitec Biopharma Inc.

NASDAQ:BNTCHealthcare
+10.42%$9.54
AH$9.54+0.00%vs close
Mkt Cap$332.84M
Float23.26M
O/S34.89M
Inst Own94.8%
SI8.6%
Dilution
Benitec Biopharma Inc. logoNASDAQ:BNTC$9.54+10.42%
Historical Data
DateOpenHighLowCloseVolume
Nov 6, 20268.659.568.559.54120,361
Nov 5, 20269.329.378.628.64311,111
Nov 4, 20268.679.398.679.28298,142
Nov 3, 20268.588.898.308.40105,817
Nov 2, 20268.818.948.248.49240,634
Oct 30, 20268.808.938.438.74135,486
Oct 29, 20268.739.118.738.83162,544
Oct 28, 20267.888.917.888.80238,600
Oct 27, 20268.608.858.528.68156,893
Oct 26, 20268.718.808.548.5998,628
Oct 23, 20268.918.918.538.65158,391
Oct 22, 20268.478.858.218.82149,010
Oct 21, 20269.059.228.408.50171,851
Oct 20, 20268.359.298.329.04347,596
Oct 19, 20268.138.628.008.36194,120
Oct 16, 20268.478.478.068.11158,558
Oct 15, 20268.378.768.348.46153,731
Oct 14, 20268.529.078.258.29162,499
Oct 13, 20269.089.088.518.63151,397
Oct 12, 20268.909.258.759.07200,903
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target (median, last 90d)
$17.00+78.2%
Low $17High $17
Ratings Distribution
BUY
7
HOLD
1
SELL
0
TOTAL8
Insider Trades
InsiderTypeShares
Friedman David Matthew profile photoFriedman David MatthewGrant/Award35.0K
Mates Sharon profile photoMates SharonGrant/Award31.5K
MONTANOVA CAPITAL, LLC profile photoMONTANOVA CAPITAL, LLCPurchase65.8K
MONTANOVA CAPITAL, LLC profile photoMONTANOVA CAPITAL, LLCPurchase11.6K
MONTANOVA CAPITAL, LLC profile photoMONTANOVA CAPITAL, LLCPurchase14.3K
MONTANOVA CAPITAL, LLC profile photoMONTANOVA CAPITAL, LLCPurchase2.5K
Shareholders
94.8%
Institutional
(89)
0.0%
Insiderⓘ
(1)
9.7%
5%+ Owners
(1)
-
Unattributed (incl. retail)ⓘ
Institutional94.8%
Insider0.0%
5%+ Beneficial9.7%
Sources: 13F, Form 4, 13D/13GO/S: 34.9M · as of 13 Oct 2026 · SEC filings
Insiders & Institutional Holders

Insiders

Top institutional holders

About

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines.

Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.

The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Key Metrics
Market Cap$332.84M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership94.84%

based on 34.89M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateJun 24, 2014
Shares Outstanding34.89M
Authorized Shares
Float23.26M
52-Week Range
$7.88$14.39
$9.54(25th percentile)
Volume
Average Daily Volume185.81K
120.36K today vs 185.81K avg(-35%)

30d Avg

185.81K

60d Avg

193.51K

90d Avg

192.05K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...